AWS GraphRAG Cut Drug Development by 87%: Unified Graph vs. Separate Databases

AWS GraphRAG Cut Drug Development Cycles by 87%: Unified Knowledge Graph Instead of Separate Databases

At a recent AWS conference, AWS presented a case study: implementing GraphRAG at a pharmaceutical company cut R&D cycles by 87%.

Problem

A pharmaceutical company worked with 10+ internal proprietary databases: molecular structures, test results, literature, clinical data, metabolic models. Researchers starting a new project:

• Query data from each system separately
• Manually integrate results
• Search for relationships between different sources
• This all took 6+ months

Solution

GraphRAG unified all databases into a single knowledge graph: nodes (molecules, tests, people) and edges (relationships between them). Now a question like "which molecules are similar to Aspirin and showed good results in liver?" queries the entire graph at once.

Results

• 87% acceleration: instead of 6+ months for screening — weeks
• Improved success rate in early phases: from 5% before
• Researchers can query the graph without learning SQL for each database

What This Means

GraphRAG shows: unifying data through a knowledge graph is not just convenience, it's a discovery accelerator. Companies with fragmented systems (and that's most of them) lose months on integration. A graph solves the problem architecturally.